Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Despite the weaker than expected results, Exact Sciences announced several pipeline advancements, including FDA approval for its next-generation Cologuard Plus test and promising data from its ...

QRG Capital Management Inc. grew its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The ...

The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a ...